Want to see ABUS full AI Analyst Report?
Arbutus Biopharma (ABUS) Financial Statements
1,286 Followers
Arbutus Biopharma Financial Overview
Arbutus Biopharma's market cap is currently $768.65M. The company's EPS TTM is $0.79; its P/E ratio is 5.13; Arbutus Biopharma is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $-0.02. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 14.08M | $ 6.17M | $ 18.14M | $ 39.02M | $ 10.99M |
| Gross Profit | $ 13.72M | $ 6.17M | $ 18.14M | $ 39.02M | $ 10.99M |
| Operating Income | $ -27.05M | $ -76.32M | $ -78.10M | $ -65.46M | $ -73.52M |
| EBITDA | $ -33.04M | $ -68.40M | $ -70.99M | $ -61.86M | $ -71.64M |
| Net Income | $ -33.50M | $ -69.92M | $ -72.85M | $ -69.46M | $ -76.25M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 91.47M | $ 122.62M | $ 126.00M | $ 146.91M | $ 155.32M |
| Total Assets | $ 94.62M | $ 131.71M | $ 144.40M | $ 195.42M | $ 204.49M |
| Total Debt | $ 4.19M | $ 6.12M | $ 8.72M | $ 12.55M | $ 18.91M |
| Net Debt | $ -13.82M | $ -30.21M | $ -17.56M | $ -18.22M | $ -90.37M |
| Total Liabilities | $ 18.04M | $ 34.34M | $ 38.38M | $ 58.57M | $ 35.05M |
| Stockholders' Equity | $ 76.58M | $ 97.37M | $ 106.02M | $ 136.85M | $ 169.44M |
| Cash Flow | |||||
| Free Cash Flow | $ -39.64M | $ -65.03M | $ -86.94M | $ -35.87M | $ -68.34M |
| Operating Cash Flow | $ -39.64M | $ -64.85M | $ -85.94M | $ -35.36M | $ -67.53M |
| Investing Cash Flow | $ 15.58M | $ 22.95M | $ 50.77M | $ -74.94M | $ -12.68M |
| Financing Cash Flow | $ 5.72M | $ 52.00M | $ 30.65M | $ 31.81M | $ 137.24M |
Currency in USD
